[go: up one dir, main page]

WO2025024400A3 - Substituted tryptamines and uses thereof - Google Patents

Substituted tryptamines and uses thereof Download PDF

Info

Publication number
WO2025024400A3
WO2025024400A3 PCT/US2024/039061 US2024039061W WO2025024400A3 WO 2025024400 A3 WO2025024400 A3 WO 2025024400A3 US 2024039061 W US2024039061 W US 2024039061W WO 2025024400 A3 WO2025024400 A3 WO 2025024400A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
aspects
tryptamines
methods
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/039061
Other languages
French (fr)
Other versions
WO2025024400A2 (en
Inventor
David Nichols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
2a Biosciences Inc
Original Assignee
2a Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2a Biosciences Inc filed Critical 2a Biosciences Inc
Publication of WO2025024400A2 publication Critical patent/WO2025024400A2/en
Publication of WO2025024400A3 publication Critical patent/WO2025024400A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates in some aspects to certain substituted tryptamines, such as tryptamines containing 2,7-dialkyl or 2-halo-7-alkyl substitution on the indole ring. Also provided are methods of synthesizing the compounds, compositions containing the compounds, and methods of using the compounds and compositions. In some aspects, features of the compounds include neuromodulatory activity, for example, activation of serotonin receptors. In some further aspects, the compounds are useful as therapeutic agents, such as anti-inflammatory agents.
PCT/US2024/039061 2023-07-21 2024-07-22 Substituted tryptamines and uses thereof Pending WO2025024400A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363528259P 2023-07-21 2023-07-21
US63/528,259 2023-07-21

Publications (2)

Publication Number Publication Date
WO2025024400A2 WO2025024400A2 (en) 2025-01-30
WO2025024400A3 true WO2025024400A3 (en) 2025-03-06

Family

ID=94375683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/039061 Pending WO2025024400A2 (en) 2023-07-21 2024-07-22 Substituted tryptamines and uses thereof

Country Status (1)

Country Link
WO (1) WO2025024400A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870162A (en) * 1954-04-28 1959-01-20 Upjohn Co Production of certain tryptamines and compounds produced in the process
US20200030309A1 (en) * 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
US20220096504A1 (en) * 2019-01-30 2022-03-31 Diamond Therapeutics Inc. Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavorial, and/or mood disorders
US20220251040A1 (en) * 2019-02-27 2022-08-11 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US11660305B2 (en) * 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870162A (en) * 1954-04-28 1959-01-20 Upjohn Co Production of certain tryptamines and compounds produced in the process
US20200030309A1 (en) * 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
US20220096504A1 (en) * 2019-01-30 2022-03-31 Diamond Therapeutics Inc. Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavorial, and/or mood disorders
US20220251040A1 (en) * 2019-02-27 2022-08-11 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
US11660305B2 (en) * 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth

Also Published As

Publication number Publication date
WO2025024400A2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
DK0593513T3 (en) Tryptamine analogues, their synthesis and their use as 5-HT, -like or 5-HT2 receptor agonists
ATE423769T1 (en) FLUORINE AND SULFONYLAMINO CONTAINING, 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES AS MUSCARINO RECEPTOR ANTAGONISTS
BG106539A (en) Bicyclic androgen and progesterone receptor modulator compounds and methods
MX2021001690A (en) Substituted indoles and methods of use thereof.
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
NZ208529A (en) 2-pyrimidinyl-1-piperazine derivatives and pharmaceutical compositions
DE69400824D1 (en) INDOL DERIVATIVES AS 5-HT1-LIKE ANTAGONISTS FOR TREATING MIGRAINE
MX2023002579A (en) Azetidinyl tryptamines and methods of treating psychiatric disorders.
BR0311593A (en) 1-Sulphonyl-4-aminoalkoxy indole derivatives as 5-ht6 receptor modulators for treatment of snc disorders
NO20061845L (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
MX2023010316A (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto.
MX2007011695A (en) Substituted oxindole derivatives, medicaments containing the latter and use thereof.
WO2022115944A8 (en) Carboxylated psilocybin derivatives and methods of using
ATE307133T1 (en) HEXAHYDROAZEPINO(4.5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS
MX2025002166A (en) Compounds and methods for modulating her2
WO2025024400A3 (en) Substituted tryptamines and uses thereof
MX2007011698A (en) Substituted oxindole derivatives, medicaments containing the latter and use thereof.
BR9305991A (en) Indole derivatives as steroid 5 alpha reductase inhibitors
EA202190322A1 (en) IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AS TRK INHIBITORS
MX2025002501A (en) Indoline derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2022204344A3 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
MXPA05013256A (en) 1- (alkylaminoalkyl-pyrolidin-/piperidinyl) -2, 2-diphenylacetamide derivatives as muscarinic receptor antagonists.
CA3156320A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists
MX2022004215A (en) 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24846340

Country of ref document: EP

Kind code of ref document: A2